Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices

被引：21

作者：

Rockey D.C. ^{[1
]}

机构：

[1] Division of Digestive and Liver Diseases, University of Texas, Southwestern Medical Center, Dallas, TX 75390-8887

来源：

Current Gastroenterology Reports | 2006年 / 8卷 / 1期

关键词：

Octreotide; Portal Hypertension; Transjugular Intrahepatic Portosystemic Shunt; Esophageal Varix; Variceal Bleeding;

D O I：

10.1007/s11894-006-0058-9

中图分类号：

学科分类号：

摘要：

Cirrhosis results in portal hypertension in many patients. The major complications of portal hypertension include development of ascites and esophageal or gastric varices. Varices lead to hemorrhage and death in a significant proportion of patients. This review focuses on the pharmacologic approach to management of portal hypertension in patients at risk of variceal hemorrhage, or those who have already had variceal bleeding. Pharmacologic therapy is used for 1) primary prevention of bleeding, 2) management of acute bleeding, and 3) prevention of recurrent bleeding (secondary prophylaxis). For acute esophageal variceal hemorrhage, a variety of pharmacologic agents are used, including somatostatin, octreotide, vapreotide, lanreotide, terlipressin, and vasopressin (with nitrates). For primary and secondary prevention of esophageal variceal hemorrhage, β-blockers remain the mainstay therapy. Copyright © 2006 by Current Science Inc.

引用

页码：7 / 13

页数：6

共 58 条

[1]

Chalasani N., Kahi C., Francois F., Et al., Improved patient survival after acute variceal bleeding: A multicenter, cohort study, Am J Gastroenterol, 98, pp. 653-659, (2003)

[2]

van Leerdam M.E., Vreeburg E.M., Rauws E.A., Et al., Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000, Am J Gastroeoterol, 98, pp. 1494-1499, (2003)

[3]

D'Amico G., De Franchis R., Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators, Hepatology, 38, pp. 599-612, (2003)

[4]

Rockey D.C., Vascular mediators in the injured liver, Hepatology, 37, pp. 4-12, (2003)

[5]

Viallet A., Marleau D., Huet M., Et al., Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient, Gastroenterology, 69, pp. 1297-1300, (1975)

[6]

Lebrec D., De Fleury P., Rueff B., Et al., Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis, Gastroenterology, 79, pp. 1139-1144, (1980)

[7]

Garcia-Tsao C., Groszmann R.J., Fisher R.L., Et al., Portal pressure, presence of gastroesophageal varices and variceal bleeding, Hepatology, 5, pp. 419-424, (1985)

[8]

Cales P., Pascal J.P., Gastroesophageal endoscopic features in cirrhosis: Comparison of intracenter and intercenter observer variability, Gastroenterology, 99, (1990)

[9]

Ng F.H., Wong S.Y., Loo C.K., Et al., Prediction of oesopha gogastric varices in patients with liver cirrhosis, J Gastroenterol Hepatol, 14, pp. 785-790, (1999)

[10]

Chalasani N., Imperiale T.F., Ismail A., Et al., Predictors of large esophageal varices in patients with cirrhosis, Am J Gastroenterol, 94, pp. 3285-3291, (1999)

← 1 2 3 4 5 6 →